Physician profile
Melissa Rienstra
NPI 1407351117
$2,463.95
in general payments reported to CMS, 2019-2025
31 companies · $732 in 2025
The $732 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.76 · 2022: $203 · 2023: $634 · 2024: $796 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $270.81 | 2022-2025 | |
| Lilly USA, LLC | $263.85 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $233.86 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $230.97 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $205.70 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $149.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $122.47 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.41 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $95.40 | 2023-2024 | Xarelto, Spravato |
| Dexcom, INC. | $91.43 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $80.44 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $78.73 | 2023-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $75.39 | 2021-2024 | |
| Abbvie INC. | $71.66 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.85 | 2023-2024 | Xifaxan, Trulance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $43.05 | 2021-2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $42.00 | 2025 | |
| Astellas Pharma US INC | $25.38 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $23.00 | 2023 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $22.20 | 2025 | Opsumit, Uptravi |
| Lundbeck LLC | $21.96 | 2023 | Rexulti |
| Corcept Therapeutics | $20.71 | 2024 | Korlym |
| Phathom Pharmaceuticals, INC. | $18.27 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $18.18 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.82 | 2021 | |
| Boston Scientific Corporation | $16.56 | 2025 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $14.75 | 2023 | |
| Eisai INC. | $14.07 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.02 | 2023 | Quviviq |
| Exeltis, USA INC. | $12.69 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Rienstra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.